Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$21.27 +0.4%	$24.35	$21.09 ▼ $53.96	$998.41M	0.72	499,488 shs	675,607 shs
MRNA Moderna	$32.06 +1.5%	$27.62	$23.15 ▼ $126.42	$12.21B	1.84	8.90 million shs	5.97 million shs
OCGN Ocugen	$1.04 -2.8%	$0.96	$0.52 ▼ $1.93	$312.47M	4.18	4.57 million shs	3.59 million shs
PFE Pfizer	$24.59 -0.1%	$23.99	$20.92 ▼ $31.54	$139.92B	0.58	41.95 million shs	44.17 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	-3.51%	-6.28%	-17.97%	-7.87%	-45.36%
MRNA Moderna	-3.92%	-2.95%	+18.41%	+25.37%	-74.00%
OCGN Ocugen	-3.60%	+1.90%	-5.31%	+63.81%	-43.98%
PFE Pfizer	-2.88%	-3.85%	+0.47%	+11.68%	-15.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMPH Amphastar Pharmaceuticals	4.2922 of 5 stars	3.1	2.0	0.0	3.7	1.9	4.2	1.3
MRNA Moderna	4.4301 of 5 stars	4.0	1.0	0.0	4.6	3.2	2.5	0.6
OCGN Ocugen	1.3749 of 5 stars	3.5	1.0	0.0	0.0	2.7	0.0	0.0
PFE Pfizer	4.9588 of 5 stars	3.2	3.0	4.2	4.5	2.6	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	2.25	Hold	$32.33	52.01% Upside
MRNA Moderna	2.04	Hold	$46.61	45.39% Upside
OCGN Ocugen	3.00	Buy	$6.00	476.92% Upside
PFE Pfizer	2.45	Hold	$28.55	16.11% Upside

Current Analyst Ratings Breakdown

Latest OCGN, MRNA, PFE, and AMPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/13/2025	MRNA Moderna	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight
7/13/2025	MRNA Moderna	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight
7/13/2025	MRNA Moderna	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold ➝ Hold
6/24/2025	OCGN Ocugen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
6/24/2025	OCGN Ocugen	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
6/2/2025	MRNA Moderna	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
5/29/2025	PFE Pfizer	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold	$28.00 ➝ $25.00
5/22/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$33.00 ➝ $26.00
5/21/2025	PFE Pfizer	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $33.00
5/19/2025	PFE Pfizer	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy	$27.00 ➝ $26.00
5/12/2025	AMPH Amphastar Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$45.00 ➝ $30.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$731.97M	1.37	$5.03 per share	4.23	$15.23 per share	1.40
MRNA Moderna	$3.24B	3.83	N/A	N/A	$28.33 per share	1.13
OCGN Ocugen	$4.05M	74.99	N/A	N/A	$0.10 per share	10.40
PFE Pfizer	$63.63B	2.20	$4.36 per share	5.64	$15.62 per share	1.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$159.52M	$2.76	7.71	6.47	5.52	19.38%	22.20%	10.40%	8/6/2025 (Estimated)
MRNA Moderna	-$3.56B	-$8.73	N/A	N/A	N/A	-105.67%	-28.69%	-21.94%	7/30/2025 (Estimated)
OCGN Ocugen	-$54.05M	-$0.19	N/A	N/A	N/A	-1,271.12%	-223.00%	-92.20%	8/14/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	17.82	8.11	0.90	12.62%	20.33%	8.53%	8/5/2025 (Estimated)

Latest OCGN, MRNA, PFE, and AMPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	MRNA Moderna	-$2.97	N/A	N/A	N/A	$116.26 million	N/A
8/6/2025	Q2 2025	AMPH Amphastar Pharmaceuticals	$0.71	N/A	N/A	N/A	$173.42 million	N/A
8/5/2025	Q2 2025	PFE Pfizer	$0.57	N/A	N/A	N/A	$13.43 billion	N/A
5/9/2025	Q1 2025	OCGN Ocugen	-$0.06	-$0.05	+$0.01	-$0.05	N/A	$1.48 million
5/1/2025	Q1 2025	MRNA Moderna	-$2.92	-$2.52	+$0.40	-$2.52	$130.35 million	$108.00 million
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	7.00%	N/A	124.64%	16 Years

Latest OCGN, MRNA, PFE, and AMPH Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.80	2.95	2.02
MRNA Moderna	N/A	4.22	4.14
OCGN Ocugen	1.74	2.60	2.60
PFE Pfizer	0.64	1.26	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
MRNA Moderna	75.33%
OCGN Ocugen	10.27%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	27.50%
MRNA Moderna	11.00%
OCGN Ocugen	4.42%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	2,028	47.14 million	34.18 million	Optionable
MRNA Moderna	5,800	386.74 million	344.20 million	Optionable
OCGN Ocugen	80	292.03 million	279.12 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

OCGN, MRNA, PFE, and AMPH Headlines

Recent News About These Companies

Morningstar Reduces Moat Rating For Pfizer (PFE) To Narrow

5 hours ago | finance.yahoo.com

Pfizer (NYSE:PFE) Trading 1.1% Higher - Time to Buy?

July 16 at 1:53 PM | marketbeat.com

Pfizer’s Hemophilia Study Completion: Market Implications and Insights

July 16 at 12:16 PM | tipranks.com

Pfizer’s INLYTA® Study Completion: Real-World Insights and Market Impact

July 16 at 12:16 PM | tipranks.com

Pfizer’s Latest Clinical Study: A New Hope for Advanced Melanoma Treatment?

July 16 at 12:16 PM | tipranks.com

Allen Capital Group LLC Acquires 17,454 Shares of Pfizer Inc. (NYSE:PFE)

July 16 at 10:02 AM | marketbeat.com

Summit X LLC Buys 12,786 Shares of Pfizer Inc. (NYSE:PFE)

July 16 at 9:21 AM | marketbeat.com

DDD Partners LLC Takes $817,000 Position in Pfizer Inc. (NYSE:PFE)

July 16 at 7:53 AM | marketbeat.com

Whittier Trust Co. Sells 19,083 Shares of Pfizer Inc. (NYSE:PFE)

July 16 at 6:23 AM | marketbeat.com

This Once-Dominant Healthcare Stock Down 50% Is Finally Ready for a Comeback

July 16 at 5:00 AM | fool.com

Jim Cramer Says Pfizer Needs a Catalyst

July 16 at 2:44 AM | msn.com

Pfizer (NYSE:PFE) Stock Price Down 2.3% - Should You Sell?

July 15 at 3:21 PM | marketbeat.com

Morningstar Reduces Moat Rating For Pfizer (PFE) To Narrow

July 15 at 12:31 PM | insidermonkey.com

Ex-Pfizer Doctor Tells Congress He Didn’t Delay Covid Shot Data

July 15 at 11:40 AM | msn.com

How Will Pfizer's Oncology Drugs Perform in Q2 Earnings?

July 15 at 11:40 AM | msn.com

Don’t Miss These 4 Stocks With Explosive Dividend Yields (PFE)

July 15 at 10:16 AM | dividendstocks.comD

How Will Pfizer's Oncology Drugs Perform in Q2 Earnings?

July 15 at 9:55 AM | zacks.com

Tectonic Advisors LLC Grows Stock Holdings in Pfizer Inc. (NYSE:PFE)

July 15 at 9:12 AM | marketbeat.com

Kornitzer Capital Management Inc. KS Increases Stake in Pfizer Inc. (NYSE:PFE)

July 15 at 8:54 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Position Raised by Concord Asset Management LLC VA

July 15 at 8:51 AM | marketbeat.com

Patrick Mauro Investment Advisor INC. Buys 65,440 Shares of Pfizer Inc. (NYSE:PFE)

July 15 at 7:55 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Top 5 Undervalued Dividend Stocks With Strong Payout Potential
By Ryan Hasson | July 7, 2025
View Top 5 Undervalued Dividend Stocks With Strong Payout Potential

OCGN, MRNA, PFE, and AMPH Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$21.27 +0.09 (+0.42%)

Closing price 04:00 PM Eastern

Extended Trading

$21.64 +0.37 (+1.72%)

As of 07:14 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Moderna NASDAQ:MRNA

$32.06 +0.48 (+1.52%)

Closing price 04:00 PM Eastern

Extended Trading

$32.08 +0.02 (+0.06%)

As of 07:58 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Ocugen NASDAQ:OCGN

$1.04 -0.03 (-2.80%)

Closing price 04:00 PM Eastern

Extended Trading

$1.04 0.00 (0.00%)

As of 07:56 PM Eastern

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Pfizer NYSE:PFE

$24.59 -0.02 (-0.09%)

Closing price 03:59 PM Eastern

Extended Trading

$24.62 +0.03 (+0.13%)

As of 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time